INCY
Price
$88.06
Change
+$0.76 (+0.87%)
Updated
Oct 22 closing price
Capitalization
17.2B
5 days until earnings call
Intraday Buy/Sell Signals
REGN
Price
$584.74
Change
+$5.40 (+0.93%)
Updated
Oct 22 closing price
Capitalization
61.98B
5 days until earnings call
Intraday Buy/Sell Signals
Interact to see
Advertisement

INCY vs REGN

Header iconINCY vs REGN Comparison
Open Charts INCY vs REGNBanner chart's image
Incyte
Price$88.06
Change+$0.76 (+0.87%)
Volume$1.58M
Capitalization17.2B
Regeneron Pharmaceuticals
Price$584.74
Change+$5.40 (+0.93%)
Volume$691.26K
Capitalization61.98B
INCY vs REGN Comparison Chart in %
INCY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
REGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
INCY vs. REGN commentary
Oct 23, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is INCY is a StrongBuy and REGN is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 23, 2025
Stock price -- (INCY: $88.06 vs. REGN: $584.74)
Brand notoriety: INCY and REGN are both notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: INCY: 86% vs. REGN: 63%
Market capitalization -- INCY: $17.2B vs. REGN: $61.98B
INCY [@Biotechnology] is valued at $17.2B. REGN’s [@Biotechnology] market capitalization is $61.98B. The market cap for tickers in the [@Biotechnology] industry ranges from $109.34B to $0. The average market capitalization across the [@Biotechnology] industry is $2.05B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

INCY’s FA Score shows that 1 FA rating(s) are green whileREGN’s FA Score has 1 green FA rating(s).

  • INCY’s FA Score: 1 green, 4 red.
  • REGN’s FA Score: 1 green, 4 red.
According to our system of comparison, INCY is a better buy in the long-term than REGN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

INCY’s TA Score shows that 5 TA indicator(s) are bullish while REGN’s TA Score has 5 bullish TA indicator(s).

  • INCY’s TA Score: 5 bullish, 2 bearish.
  • REGN’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, INCY is a better buy in the short-term than REGN.

Price Growth

INCY (@Biotechnology) experienced а -0.10% price change this week, while REGN (@Biotechnology) price change was +1.44% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.28%. For the same industry, the average monthly price growth was +10.37%, and the average quarterly price growth was +61.79%.

Reported Earning Dates

INCY is expected to report earnings on Oct 28, 2025.

REGN is expected to report earnings on Oct 28, 2025.

Industries' Descriptions

@Biotechnology (-2.28% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
REGN($62B) has a higher market cap than INCY($17.2B). INCY has higher P/E ratio than REGN: INCY (20.82) vs REGN (14.74). INCY YTD gains are higher at: 27.494 vs. REGN (-17.560). REGN has higher annual earnings (EBITDA): 5.42B vs. INCY (1.36B). REGN has more cash in the bank: 7.47B vs. INCY (2.42B). INCY has less debt than REGN: INCY (42.4M) vs REGN (2.71B). REGN has higher revenues than INCY: REGN (14.2B) vs INCY (4.59B).
INCYREGNINCY / REGN
Capitalization17.2B62B28%
EBITDA1.36B5.42B25%
Gain YTD27.494-17.560-157%
P/E Ratio20.8214.74141%
Revenue4.59B14.2B32%
Total Cash2.42B7.47B32%
Total Debt42.4M2.71B2%
FUNDAMENTALS RATINGS
INCY vs REGN: Fundamental Ratings
INCY
REGN
OUTLOOK RATING
1..100
7070
VALUATION
overvalued / fair valued / undervalued
1..100
69
Overvalued
3
Undervalued
PROFIT vs RISK RATING
1..100
9697
SMR RATING
1..100
3954
PRICE GROWTH RATING
1..100
1262
P/E GROWTH RATING
1..100
10085
SEASONALITY SCORE
1..100
5042

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

REGN's Valuation (3) in the Biotechnology industry is significantly better than the same rating for INCY (69). This means that REGN’s stock grew significantly faster than INCY’s over the last 12 months.

INCY's Profit vs Risk Rating (96) in the Biotechnology industry is in the same range as REGN (97). This means that INCY’s stock grew similarly to REGN’s over the last 12 months.

INCY's SMR Rating (39) in the Biotechnology industry is in the same range as REGN (54). This means that INCY’s stock grew similarly to REGN’s over the last 12 months.

INCY's Price Growth Rating (12) in the Biotechnology industry is somewhat better than the same rating for REGN (62). This means that INCY’s stock grew somewhat faster than REGN’s over the last 12 months.

REGN's P/E Growth Rating (85) in the Biotechnology industry is in the same range as INCY (100). This means that REGN’s stock grew similarly to INCY’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
INCYREGN
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bearish Trend 1 day ago
63%
Bullish Trend 1 day ago
69%
Momentum
ODDS (%)
Bullish Trend 1 day ago
63%
Bullish Trend 1 day ago
74%
MACD
ODDS (%)
Bullish Trend 1 day ago
68%
Bullish Trend 1 day ago
70%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
60%
Bullish Trend 1 day ago
65%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
60%
Bearish Trend 1 day ago
62%
Advances
ODDS (%)
Bullish Trend 1 day ago
61%
Bullish Trend 1 day ago
62%
Declines
ODDS (%)
Bearish Trend 14 days ago
59%
Bearish Trend 11 days ago
53%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
61%
Bearish Trend 4 days ago
55%
Aroon
ODDS (%)
N/A
Bearish Trend 1 day ago
65%
View a ticker or compare two or three
Interact to see
Advertisement
INCY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
REGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
EVG11.130.04
+0.36%
Eaton Vance Short Duration Diversified Income Fund
CSRE26.180.05
+0.18%
Cohen & Steers Real Estate Active ETF
JQUA62.73-0.30
-0.48%
JPMorgan US Quality Factor ETF
WBIF31.01-0.37
-1.19%
WBI BullBear Value 3000 ETF
PBW31.71-1.23
-3.73%
Invesco WilderHill Clean Energy ETF